An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis;Estudio observacional sobre la efectividad y seguridad del natalizumab en el tratamiento de la esclerosis múltiple

Revista de Neurologia

Volumn 52, Issue 6, 2011, Pages 321-330

  Horga, Alejandro ^a   Castilló, Joaquín ^a   Río, Jordi ^a   Tintoré, Mar ^a   Auger, Cristina ^a   Sastre Garriga, Jaume ^a   Edo, M Carmen ^a   Pérez Miralles, Francisco ^a   Tur, Carmen ^a   Nos, Carlos ^a   Huerga, Elena ^a   Comabella, Manuel ^a   Rovira, Àlex ^a   Montalban, Xavier ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Immunomodulatory treatment; Magnetic resonance imaging; Monoclonal antibody; Multiple sclerosis; Natalizumab; Observational study

Indexed keywords

GADOLINIUM; NATALIZUMAB;

ARTICLE; BRAIN; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; RISK BENEFIT ANALYSIS;

EID: 79953098300     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5206.2010766     Document Type: Article

References (22)

1. Horga A, Horga de la Parte JF. Natalizumab en el tratamiento de la esclerosis múltiple. Rev Neurol 2007; 45: 293-303.
2. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-72.
3. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23. (Pubitemid 36026342)
4. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-43. (Pubitemid 38738218)
5. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
6. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
7. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72: 806-12.
8. Río-Izquierdo J, Montalban X. Natalizumab en esclerosis múltiple. Rev Neurol 2009; 49: 265-9.
9. Food and Drug Administration. Drug safety communication. Risk of progressive multifocal leukoencephalopathy with the use of Tysabri. URL: http://www.fda.gov/Drugs/DrugSafety/ ucm199872.htm. [01.12.2010].
10. EMEA. EPARs for authorised medicinal products for human use: Tysabri. URL: www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000603/WC500044686.pdf. [01.12.2010].
11. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6: 431-41. (Pubitemid 46551850)
12. Rovira A, Tintoré M, Álvarez-Cermeño JC, Izquierdo G, Prieto JM. Recomendaciones para la utilización e interpretación de los estudios de resonancia magnética en la esclerosis múltiple. Neurología 2010; 25: 248-65.
13. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254-60.
14. Oturai A, Koch-Henriksen N, Petersen T, Jensen P, Sellebjerg F, Sorensen P. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16: 420-3.
15. Outteryck O, Ongagna J, Zéphir H, Fleury MC, Lacour A, Blanc F, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 2010; 257: 207-11.
16. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-7.
17. Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010; 63: 101-6.
18. Horga A, Tintoré M. Natalizumab para la esclerosis múltiple remitente-recurrente. Neurología 2010; Dec 28. [Epub ahead of print].
19. Oreja-Guevara C, Martín-Barriga ML, Gabaldón-Torres L, Lubrini G, Díaz-Tejedor E. Mejoría en la discapacidad física en pacientes con EMRR tratados con natalizumab [abstract]. Rev Neurol 2010; 50: 497-8.
20. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kumpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-3. (Pubitemid 47403090)
21. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-8.
22. Leussink VI, Lehmann HC, Hartung HP, Gold R, Kieseier BC. Type III systemic allergic reaction to natalizumab. Arch Neurol 2008; 65: 851-2. (Pubitemid 351831477)